Kornimate/medical-research-clean huggingface dataset:
egcg, a dyrk1a inhibitor as therapeutic tool for reversing cognitive deficits in down syndrome individuals.

Conditions: Down Syndrome

Summary: there is a mounting evidence of the modulation properties of the major catechin in green tea, epigallocatechin-3-gallate (egcg), on dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) gene overexpression in the brains of ds mouse models.the aims are to investigate the clinical benefits and safety of egcg administration in young adults with ds, to establish short-term egcg effects (three months) on neurocognitive performance, and to determine the persistency or reversibility of egcg related effects after three months of discontinued use.


Eligibility criteria:
inclusion criteria: * have been diagnosed of ds neurological disease, aged between 14-29 years, have given the consent to participate (official custody). exclusion criteria: * subjects with neurological disease other than ds, relevant medical disease, co-morbid mental disorder or currently taking any treatment that could interfere with cognitive function or alter any key biomarkers and biochemical parameters analyzed. * having suffered from any major illness or undergoing major surgery in the last three months before the study; * regular ingestion of medication in the month preceding the study. exceptions were made for single doses of symptomatic medication administered up to the week preceding the trial. * current ingestion of vitamin supplements or catechins or aine in the two weeks preceding the study. * history of gastrointestinal, hepatic or renal problems or any other cause that may alter processes of absorption, distribution, metabolism, or excretion of the drug, or that might suggest gastrointestinal irritation to drug. * subjects following a vegetarian diet. * practice of physical exercise for more than 2 hours per day or energy consume/consumption of more than 3000 kcal per week.
evaluation of the effectiveness of a multimedia information site in reducing preoperative anxiety in vascular surgery patients.

Conditions: Vascular Diseases

Summary: anxiety is a phenomenon that frequently occurs before surgery. preoperative anxiety has been studied in several disciplines, including rheumatology, anesthesia, stomatology and cardiology. the implications of preoperative anxiety in terms of morbidity and mortality have also been studied and are well known: intraoperative hemodynamic disorders, increased postoperative mortality, increased consumption of anesthetic agents. several scales have been developed to quantify preoperative anxiety, the most frequently used being the visual analog scale and the amsterdam scale. several approaches have been considered to reduce preoperative anxiety, such as hypnosis, music, or multimedia. however, no consensus tool has been developed for vascular surgery patients. similarly, no study has examined preoperative anxiety in this specific population. the aim of this study is to evaluate a new multimedia information medium for vascular surgery patients and to assess its effectiveness in reducing preoperative anxiety.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age * patient affiliated to a health insurance plan * french-speaking patient * patient who has given free, informed and express consent * patient who has consulted a vascular surgeon for a scheduled procedure * patient with internet and telephone access to view videos * patient referred for surgical or endovascular treatment for obliterative arteriopathy of the lower limbs, abdominal aortic aneurysm and surgical treatment for carotid stenosis exclusion criteria: * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * patients with blindness * patients with severe cognitive impairment * patients without access to a digital support to view the videos * pregnant and breastfeeding women
vertigo perception and quality of life in patients after surgical treatment of vestibular schwannoma

Conditions: Vestibular Schwannoma

Summary: surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. in general, the dominant symptom postoperatively is vertigo. preoperative chemical vestibular ablation can reduce vestibular symptoms postoperatively.

surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. in general, the dominant symptom postoperatively is vertigo. preoperative chemical vestibular ablation can reduce vestibular symptoms postoperatively. we used 1.0 ml of 40 mg/ml nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively in 10 patients. reduction of vestibular function was measured by the head impulse test and the caloric test. reduction of vestibular function was found in all gentamicin patient groups. after gentamicin vestibular ablation, patients underwent home vestibular exercising for two months. the control group consisted of 10 patients who underwent only home vestibular training two months preoperatively. postoperative rate of recovery and vertigo in both groups were evaluated with the glasgow benefit inventory (gbi), the glasgow health status inventory (ghsi) and the dizziness handicap inventory questionnaires, as well as survey of visual symptoms by specific questionnaire developed by us.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of vestibular schwannoma * hearing loss on affected side * preserved vestibular reactivity of labyrinths on the affected side exclusion criteria: * allergy to gentamicin * vestibular areflexia on the affected side

Keywords: vestibular rehabilitation
study of gut microbiome and colorectal tumors

Conditions: Serrated Polyp; Hyperplastic Polyp; Sessile Serrated Adenoma; Colorectal Cancer

Summary: gut microbiota were assessed in 540 colonoscopy-screened adults by 16s rrna gene sequencing of stool samples. investigators compared gut microbiota diversity, overall composition, and normalized taxon abundance among these groups.

colorectal cancer is a heterogeneous disease arising from at least two precursors-the conventional adenoma (ca) and the serrated polyp. a relationship between the human gut microbiota and colorectal cancer has been shown; however, its relationship to the different early precursors of colorectal cancer is understudied. this study tested, for the first time, the relationship of the gut microbiota to specific colorectal polyp types.

Eligibility criteria:
inclusion criteria: * both men and women who have visited a gastroenterologist or surgeon, aged 18 or older will be included in this study. * both men and women residents in the united states, aged 18 or older will be included in this study. exclusion criteria: * women who are pregnant will be excluded from participating in this study * subjects on ongoing antibiotic therapy will be excluded from participating in this study.
glycopyrronium and formoterol fumarate (gff) metered dose inhaler (mdi) dose indicator study in adults with moderate to very severe copd

Conditions: COPD

Summary: this is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the glycopyrronium and formoterol fumarate (gff) metered dose inhaler (mdi) dose indicator in adult subjects with moderate to very severe copd over a 4-week treatment period.


Eligibility criteria:
inclusion criteria: * give their signed written informed consent to participate. * are at least 40 years of age and no older than 80 at visit 1. * a female of non-child bearing potential or child bearing potential, has a negative serum pregnancy test, and agrees to approved contraceptive methods. * copd diagnosis: subjects with an established clinical history of copd as defined by the american thoracic society(ats)/european respiratory society (ers). * current or former smokers with a history of at least 10 pack-years of cigarette smoking. * fev1/fvc ratio of \<0.70. * post-bronchodilator fev1 must be ≥ 30% and \<80% predicted normal value calculated using the third national health and nutrition examination survey (nhanes iii) reference equations, and must also be greater than or equal to 750 ml. * subject is willing and, in the opinion of the investigator, able to adjust current copd therapy as required by the protocol. exclusion criteria: * pregnancy, nursing females or subjects trying to conceive. * clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study. * current primary diagnosis of asthma. * history of ecg abnormalities. * poorly controlled or worsening copd prior to screening or during the screening period. * clinically significant bladder neck obstruction or urinary retention. * male subjects with a trans-urethral resection of prostate (turp) or full resection of the prostate within 6 months prior to screening. * cancer that has not been in complete remission for at least five years. * inadequately treated glaucoma. * history of allergic reaction or hypersensitivity to any component of the formulations used in this study.
self-help group for the treatment of hoarding disorder

Conditions: Hoarding Disorder

Summary: the proposed study aims to investigate the efficacy of a facilitated self-help group for the treatment of hoarding disorder. eligible participants will take part in a facilitated self-help group. the investigators aim to investigate the effects of a self-help group on hoarding symptoms. the investigators hypothesize that participants will demonstrate decreased hoarding symptoms over time.


Eligibility criteria:
inclusion criteria: * clinically relevant symptoms of hoarding disorder exclusion criteria: * under 18 * psychotic disorders, bipolar disorder, substance abuse or dependence

Keywords: hoarding compulsive hoarding self-help
impact of an information assistance application in addition to a traditional anesthesia consultation on preoperative anxiety in pediatrics: prospective randomized trial

Conditions: Pediatric Surgery

Summary: the objective of the study is to evaluate the benefits on pre-operative anxiety of an information assistance application in addition to a traditional anesthesia consultation on preoperative anxiety in pediatrics


Eligibility criteria:
inclusion criteria: * child between 4 years old (inclusive) and 10 years old (inclusive); * must benefit from programmed general anesthesia for scheduled surgery at the rouen university hospital, in the paediatrics ward; * benefiting from a social security scheme; * whose parental authority has consented to participation in the research; * not having expressed their refusal to participate in the research; * understanding french; * ability to access the application being researched. exclusion criteria: * patient with cognitive disorders: disorders known in the history and assessed or suspected during the anesthesia consultation. * poor understanding of oral french by the child; * poor understanding of the oral and/or written french language by the parent/legal representative; * patient presenting a contraindication to general anesthesia or to the intervention during the pre-anaesthetic visit; * patient with severe psychiatric disorders
effect of dexmedetomidine on postoperative cognitive function in patients undergoing shoulder arthroscopy with beach chair position under desflurane anesthesia

Conditions: Rotator Cuff Tear

Summary: investigate the effects of dexmedetomidine on postoperative cognitive function in patients undergoing shoulder arthroscopy with beach chair position under desflurane anesthesia.


Eligibility criteria:
inclusion criteria: 1. patients undergoing shoulder arthroscopic surgery with beach chair position exclusion criteria: 1. patients with respiratory disease 2. patients with cardiac disease 3. patients with cerebrovascular disease 4. patients with uncontrolled hypertension 5. patients with dementia 6. patients with psychiatric disease

Keywords: cognitive function desflurane dexmedetomidine
microbial growth in operative splash basins during total joint arthroplasty

Conditions: Periprosthetic Joint Infection

Summary: the usage of splash basins in the setting of total knee arthroplasty and total hip arthroplasty presents a risk of contamination and subsequent periprosthetic joint infection. previous studies have investigated the efficacy of multiple antimicrobial irrigants for preventing periprosthetic joint infection, but the results are varied. despite several noteworthy studies on the appropriate usage of different antiseptic solutions in surgical splash basins, the current literature has several limitations. first, there are no head-to-head clinical trials comparing betadine and chlorhexidine gluconate (chg) usage with relation to periprosthetic joint infection and splash basin contamination rates. second, the in vitro studies directly cultured splash basin antiseptic solutions rather than culturing surgical instruments. the objective of this study is to compare the microbial contamination rate of total joint arthroplasty instruments that have been placed in surgical splash basins filled with either sterile water, 3.5% betadine, or 0.05% chg. the overall purpose of the study is to investigate the efficacy of 0.05% chg and determine if it is an appropriate solution to use in surgical splash basins for joint replacement surgeries. a prospective clinical trial will be conducted. patients treated at the keck hospital of usc or usc verdugo hills hospital for primary total hip or total knee arthroplasty will be screened for inclusion in our study. all primary surgeries will be performed according to the preferences of the operating surgeon. no deviations from standard surgical care will be made based on inclusion in this study. however, prior to surgery, patients who elect to participate will be randomized to one of three groups: (1) sterile water, (2) 3.5% betadine, or (3) 0.05% chg.


Eligibility criteria:
inclusion criteria: * patients presenting to keck hospital of usc or usc verdugo hills hospital for primary total knee arthroplasty or total hip arthroplasty. exclusion criteria: * age \< 18 years. * history of previous total hip arthroplasty or total knee arthroplasty. * history of previous knee or hip joint infection. * history of previous allergic reaction to chlorhexidine. * known allergy to iodine or shellfish.
effect of recombinant fviii in healthy male subjects treated with tb-402

Conditions: Healthy

Summary: single administration of recombinant fviii/placebo in healthy male subjects who have been treated with a single dose of anti-factor viii antibody, tb-402


Eligibility criteria:
inclusion criteria include: * males 18 to 45 years of age * healthy according to medical history, physical exam, ecg, blood pressure and heart rate, and laboratory profile of blood and urine exclusion criteria include: * self or family history of cardiovascular or pulmonary disorder, or coagulation or bleeding disorders or reasonable suspicion of vascular malformations e.g. cerebral haemorrhage, aneurysm or premature stroke * history of important bleeding episodes * previous allergic reaction to immunoglobulin * present or previous history of severe allergy, for example asthma or anaphylactic reactions * fviii:c \ 150% at screening * clinically significant out of range values for any coagulation test during screening * received prescribed medication, over the counter medication or herbal medicines within 14 days of receipt of tb-402

Keywords: interaction with recombinant fviii
study of induction therapy with mitoxantrone and plasmapheresis to treat aggressive multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis


Eligibility criteria:
inclusion criteria: * aggressive multiple sclerosis in attack phase * edss: 1-5 * no contraindication for mitoxantrone prescription * no past history of mitoxantrone injection * no history of corticosteroid and immunosuppressive therapy in last 3 months exclusion criteria: * patient's incompliance * severe drug induced side effects

Keywords: multiple sclerosis mitoxantrone plasmapheresis induction therapy
catch - catheter infections in children

Conditions: Catheter-related Infections

Summary: most children admitted to paediatric intensive care units (picu) need to have medicines given to them into their veins using a narrow tube, so they do not need repeated injections. this tube is called a central venous catheter. occasionally these catheters can cause infections in the blood and sometimes the tubes can get blocked by small blood clots. some intensive care units already use antibiotic or heparin coated catheters, but there is no proof that these are better than the standard ones at preventing infections. most of the picu's in this country use standard lines. the only way to find out for certain is to compare children who are given antibiotic or heparin coated catheters with those who are given standard ones in a clinical trial. because we do not know which type of catheter is best, the type of catheter each child receives in the study will be decided randomly by chance. each child in the trial will have the same chance of getting any of these three catheters: * standard central venous catheter (not coated). * heparin coated central venous catheter. heparin is a medicine that can stop blood from clotting and might stop the tubes being blocked and infections in the blood. * antibiotic coated central venous catheter. antibiotics can be used to kill bacteria which cause the infections. the aim of this study is to see how the three types of catheters compare in reducing the amount of blood infections in children. we will also look at the costs involved. we hope to recruit 1200 children in the uk over 2 years. we hope that the information we get from this study will guide policy about purchasing impregnated central venous catheters across the nhs and thereby improve treatment for children in the future.


Eligibility criteria:
inclusion criteria: * weighing ≥3kg and less than 16 years of age; * admitted to or being prepared for admission to an intensive care unit participating in the trial; * require insertion of a polyurethane cvc as part of good clinical management; * require one of the cvc sizes available to the trial (see appendix a for the list of cvcs); * expected to require a cvc for at least 3 days; * appropriate consent obtained (prospective consent for elective surgical patients, deferred consent for emergency admission patients).

Keywords: central venous catheters blood stream infection children, intensive care heparin bonded antibiotic coated children in paediatric intensive care unit
study of radiolabeled revumenib in adults with acute leukemia

Conditions: Acute Leukemia

Summary: this is an open-label study to evaluate the absorption, metabolism, and excretion (ame) of carbon-14 (\[14c\])-revumenib in participants with acute leukemia.

participants will be enrolled in this study primarily to complete the 11-day ame portion of the study; participants who are receiving benefit from revumenib may remain on study until progressive disease (pd) or unacceptable toxicity.

Eligibility criteria:
key inclusion criteria: * males and females (of non-childbearing potential) aged ≥18 years * relapsed or refractory acute leukemia, including participants who are mrd-positive by multiparametric flow cytometry or next-generation sequencing, and including participants with isolated extramedullary disease. * previously received standard of care therapy * eastern cooperative oncology group (ecog) performance status score of 0 to 2 * adequate liver and cardiac function * fertile males agree to use barrier contraception from the time of enrollment through 120 days after the last study drug dose key exclusion criteria: * active diagnosis of acute promyelocytic leukemia * white blood cell (wbc) count \>25,000/microliters at time of enrollment. * detectable human immunodeficiency virus viral load within the previous 6 months * hepatitis b or hepatitis c * cardiac, gastrointestinal, or graft-versus-host disease (gvhd) * history of or any concurrent condition, therapy, laboratory abnormality, or allergy to excipients that might confound the results of the study, interfere with the participant's ability to participate for the full duration of the study, or not be in the best interest of the participant to participate * must not be receiving any moderate or strong cytochrome p450 3a4 (cyp3a4) inhibitor/inducers * any commercially available or investigational antileukemic therapy other than revumenib except for short-term administration of corticosteroids and/or hydroxyurea for cytoreduction * participation in another therapeutic interventional clinical study in which an investigational agent was administered within 30 days before starting revumenib * any concurrent systemic treatment to prevent gvhd

Keywords: sndx-5613 acute leukemia refractory leukemia relapsed leukemia
mesh fixation versus non fixation in laparoscopic inguinal hernioplasty

Conditions: Laparoscopic; Inguinal Hernia; Hernioplasty

Summary: inguinal hernia is one of the most common types of abdominal hernias. laparoscopic hernioplasty of inguinal hernia is a good alternative to traditional open repairs even in simple unilateral primary inguinal hernia in terms of decrease post operative pain and complications with comparable recurrence rates.two techniques are described in laparoscopic hernioplasty and have been extensively studied in randomised trials. the totally extraperitoneal (tep) approach is more widely used than the transabdominal preperitoneal (tapp) approach. in this study we will compare between the results of mesh fixation and non fixation as regard operative and postoperative data.


Eligibility criteria:
inclusion criteria: * any male or female above 18 years old that has uncomplicated inguinal hernia exclusion criteria: * patients with contraindications to use laparoscopy as cardiac or immunocompromised patients. * patients who are difficult to follow up.
evaluating sarc-f, sarc-calf, and calf circumference as diagnostic tools for sarcopenia in thai older adults: results from a nationwide study

Conditions: Sarcopenia; Diagnosis

Summary: as the elderly population grows, musculoskeletal disorders, including sarcopenia, have become a critical area of study due to their association with falls and fractures. sarcopenia, characterized by decreased muscle mass, is prevalent among older adults and poses a significant risk for falls. this study aimed to assess the effectiveness of the sarc-f and sarc-calf questionnaires, along with calf circumference measurements, in screening for sarcopenia among thai community-dwelling older adults, following the asian working group on sarcopenia (awgs) 2019 criteria.

the data utilized in this analysis were derived from the thai musculoskeletal diseases nationwide study. this cross-sectional study targeted thai adults aged 60 years and older, conducted between march 2021 and august 2022. participants were sampled using a multi-level sampling technique to ensure representativeness from community-dwelling older adults across 12 provinces, encompassing thailand's six primary geographical regions. participants were evaluated for possible sarcopenia or sarcopenia, according to awgs 2019 criteria, by using sarc-f questionnaire, calf circumference measurement, sarc-calf questionnaire, and appendicular skeletal muscle mass (asm).

Eligibility criteria:
inclusion criteria: * thai adults aged 60 years and older exclusion criteria: * missing data on sarc-f, sarc-calf, and calf circumference * unable to walk independently * bedridden individuals * neuromuscular disorders or severe comorbidities that could impair their ability to perform performance-based tests

Keywords: sarcopenia calf circumference sarc-f questionnaire diagnostic accuracy elderly